Evogene Ltd Ord (EVGN)

$0.58 -0.04 (-6.30%)
Market Cap 5.40M
Revenue (ttm) 3.85M
Net Income (ttm) -8.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220.52%
Debt to Equity Ratio 0.00
Volume 375,541
Avg Vol 597,270
Day's Range N/A - N/A
Shares Out 8.72M
Stochastic %K 46%
Beta 1.35
Analysts Strong Buy
Price Target $2.15

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commerci...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 931 1900
Fax: 972 8 946 6724
Address:
13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel
opgntozero
opgntozero Jun. 4 at 10:40 AM
$EVGN Strange, our highly praised CEO from Haviv earns almost $500,000 a year without bonuses and never buys a single share of Evogene Evogene is valued at $6 million! This entire management at Evogene is simply insane and unprofessional https://www.linkedin.com/posts/evogene_financialresults-biotechnology-lifesciences-activity-7462822232491466752-iNMU
0 · Reply
SuperBusa
SuperBusa Jun. 3 at 3:49 PM
$EVGN
0 · Reply
daytradeforlife
daytradeforlife Jun. 3 at 11:27 AM
$EVGN wtf is happening?!?!
1 · Reply
Moneymike314
Moneymike314 Jun. 2 at 7:41 PM
$EVGN bottom is in, could cause a run back to .65+
0 · Reply
cw9c
cw9c Jun. 2 at 7:36 PM
$EVGN so how are we supposed to feel about today as shareholders of this company? I mean I don't feel like I can trust management anymore if there are clearly behind the scenes actions going on that thwart any value to shareholders.
0 · Reply
Stockyear
Stockyear Jun. 2 at 6:56 PM
$EVGN This was clearly an attack by option traders to short the stock. The company has a successful test per their press release today.
2 · Reply
opgntozero
opgntozero Jun. 2 at 6:23 PM
$EVGN The persistent underperformance of Evogene has led many investors to lose confidence in its potential for recovery or growth. There seems to be a troubling disconnect between the interests of management and those of shareholders. Many feel that rather than prioritizing the creation of shareholder value, there is a focus on personal financial gain for executives. Evogene stock will go to $ 0! 100%! over haviv youre not a ceo ...anything else https://www.linkedin.com/posts/evogene_microbiometherapeutics-oncologyinnovation-activity-7467537264357687297-K6Ug
0 · Reply
cw9c
cw9c Jun. 2 at 5:21 PM
$EVGN holy hell I screwed up today...this is soo bad...I mean the volume this morning had to have literally just be dilution
2 · Reply
ikerrr
ikerrr Jun. 2 at 4:03 PM
$EVGN I think it pops before the day s over
2 · Reply
cw9c
cw9c Jun. 2 at 3:59 PM
$EVGN like every slight move up is just a balloon being shot down
0 · Reply
Latest News on EVGN
Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results

2026-06-02T12:34:46.000Z - 6 days ago

Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

2026-06-02T11:06:21.000Z - 6 days ago

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Tue, 02 Jun 2026 07:00:00 -0400 - 6 days ago

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene price target lowered to $2.15 from $2.25 at Alliance Global

2026-05-26T19:10:13.000Z - 13 days ago

Evogene price target lowered to $2.15 from $2.25 at Alliance Global

Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected

2026-05-20T14:42:55.000Z - 19 days ago

Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected

Evogene Earnings Call Transcript: Q1 2026

May 20, 2026, 9:00 AM EDT - 19 days ago

Evogene Earnings Call Transcript: Q1 2026

Evogene Earnings release: Q1 2026

May 20, 2026, 9:00 AM EDT - 19 days ago

Evogene Earnings release: Q1 2026

Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation

2026-05-20T12:29:49.000Z - 19 days ago

Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation

Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year

2026-05-20T11:11:26.000Z - 19 days ago

Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year

Evogene Reports First Quarter 2026 Financial Results

Wed, 20 May 2026 07:00:00 -0400 - 19 days ago

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Tue, 12 May 2026 08:00:00 -0400 - 27 days ago

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Thu, 07 May 2026 08:00:00 -0400 - 4 weeks ago

Evogene Schedules First Quarter 2026 Financial Results Release

Evogene price target raised to $2.25 from $1.75 at Alliance Global

2026-04-13T14:21:10.000Z - 2 months ago

Evogene price target raised to $2.25 from $1.75 at Alliance Global

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

2026-04-02T21:27:08.000Z - 2 months ago

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

Evogene receives Nasdaq minimum bid price notification

2026-04-02T20:05:46.000Z - 2 months ago

Evogene receives Nasdaq minimum bid price notification

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Thu, 02 Apr 2026 16:01:00 -0400 - 2 months ago

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Tue, 31 Mar 2026 08:00:00 -0400 - 2 months ago

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene files to sell 5.08M ordinary shares for holders

2026-03-26T20:35:48.000Z - 2 months ago

Evogene files to sell 5.08M ordinary shares for holders

Evogene Registration statement: Registration filing

Mar 26, 2026, 8:00 AM EDT - 2 months ago

Evogene Registration statement: Registration filing

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

2026-03-13T15:40:44.000Z - 3 months ago

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

Evogene Slides: Corporate presentation

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Evogene Slides: Corporate presentation

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Mon, 09 Mar 2026 09:00:00 -0400 - 3 months ago

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene Earnings Call Transcript: Q4 2025

Mar 5, 2026, 9:00 AM EST - 3 months ago

Evogene Earnings Call Transcript: Q4 2025

Evogene Annual report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 3 months ago

Evogene Annual report: Q4 2025

Evogene Quarterly report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 3 months ago

Evogene Quarterly report: Q4 2025

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

2026-03-05T12:41:07.000Z - 3 months ago

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

Evogene Earnings Review: Q4 Summary

2026-03-05T12:10:35.000Z - 3 months ago

Evogene Earnings Review: Q4 Summary

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

2026-03-05T12:09:46.000Z - 3 months ago

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Thu, 05 Mar 2026 07:00:00 -0500 - 3 months ago

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

An Overview of Evogene's Earnings

2026-03-04T19:01:57.000Z - 3 months ago

An Overview of Evogene's Earnings

Evogene Releases CEO Letter to Shareholders

Wed, 25 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene Releases CEO Letter to Shareholders

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Thu, 19 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

2026-02-17T13:33:51.000Z - 3 months ago

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

2026-02-17T13:10:12.000Z - 3 months ago

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Tue, 17 Feb 2026 08:00:00 -0500 - 3 months ago

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Wed, 11 Feb 2026 08:00:00 -0500 - 4 months ago

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Tue, 10 Feb 2026 13:20:00 -0500 - 4 months ago

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

2026-02-10T13:29:55.000Z - 4 months ago

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

2026-02-10T13:16:48.000Z - 4 months ago

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

GOOG GOOGL

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Tue, 10 Feb 2026 08:00:00 -0500 - 4 months ago

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Evogene Appoints Prof. John Irwin and Prof.

Mon, 09 Feb 2026 08:00:00 -0500 - 4 months ago

Evogene Appoints Prof. John Irwin and Prof.

Evogene (EVGN) Subsidiary Biomica Secures Licensing Deal for Innovative Cancer Therapy

2026-02-05T11:26:12.000Z - 4 months ago

Evogene (EVGN) Subsidiary Biomica Secures Licensing Deal for Innovative Cancer Therapy

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

2026-02-05T11:00:14.000Z - 4 months ago

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Wed, 04 Feb 2026 22:00:00 -0500 - 4 months ago

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Evogene (EVGN) Signs Licensing Agreement for Promising Cancer Therapy

2026-02-04T13:41:08.000Z - 4 months ago

Evogene (EVGN) Signs Licensing Agreement for Promising Cancer Therapy

Biomica and Lishan Biotech sign licensing agreement for BMC128

2026-02-04T13:05:13.000Z - 4 months ago

Biomica and Lishan Biotech sign licensing agreement for BMC128

Evogene, Unravel Biosciences announce scientific collaboration

2026-01-07T12:15:13.000Z - 5 months ago

Evogene, Unravel Biosciences announce scientific collaboration

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Jan 7, 2026, 7:00 AM EST - 5 months ago

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Evogene appoints Nissan as VP of Business Development

2025-12-30T12:10:49.000Z - 5 months ago

Evogene appoints Nissan as VP of Business Development

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Dec 30, 2025, 7:00 AM EST - 5 months ago

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Evogene Earnings Call Transcript: Q3 2025

Nov 20, 2025, 9:00 AM EST - 7 months ago

Evogene Earnings Call Transcript: Q3 2025

Evogene Quarterly report: Q3 2025

Nov 20, 2025, 9:00 AM EST - 7 months ago

Evogene Quarterly report: Q3 2025

Evogene Reports Third Quarter 2025 Financial Results

Nov 20, 2025, 7:00 AM EST - 7 months ago

Evogene Reports Third Quarter 2025 Financial Results

Evogene’s Casterra and Fantini announce strategic collaboration

2025-11-11T12:11:04.000Z - 7 months ago

Evogene’s Casterra and Fantini announce strategic collaboration

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Nov 11, 2025, 7:00 AM EST - 7 months ago

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Evogene Schedules Third Quarter 2025 Financial Results Release

Nov 6, 2025, 9:00 AM EST - 7 months ago

Evogene Schedules Third Quarter 2025 Financial Results Release

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Aug 28, 2025, 7:00 AM EDT - 10 months ago

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Evogene reports Q2 EPS (10c) vs. (5c) last year

2025-08-22T09:55:14.000Z - 10 months ago

Evogene reports Q2 EPS (10c) vs. (5c) last year

Evogene Earnings Call Transcript: Q2 2025

Aug 19, 2025, 9:00 AM EDT - 10 months ago

Evogene Earnings Call Transcript: Q2 2025

Evogene Quarterly report: Q2 2025

Aug 19, 2025, 9:00 AM EDT - 10 months ago

Evogene Quarterly report: Q2 2025

Evogene reports Q2 cont ops EPS (50c) vs. (85c) last year

2025-08-19T11:10:51.000Z - 10 months ago

Evogene reports Q2 cont ops EPS (50c) vs. (85c) last year

Evogene Reports Second Quarter 2025 Financial Results

Aug 19, 2025, 7:00 AM EDT - 10 months ago

Evogene Reports Second Quarter 2025 Financial Results

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Evogene Schedules Second Quarter 2025 Financial Results Release

Jul 29, 2025, 7:00 AM EDT - 11 months ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Jul 8, 2025, 7:00 AM EDT - 11 months ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Evogene Slides: Company Presentation

Jun 1, 2025, 6:00 AM EDT - 1 year ago

Evogene Slides: Company Presentation

Evogene Earnings Call Transcript: Q1 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Evogene Earnings Call Transcript: Q1 2025

Evogene Quarterly report: Q1 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Evogene Quarterly report: Q1 2025

Evogene Reports First Quarter 2025 Financial Results

May 21, 2025, 7:00 AM EDT - 1 year ago

Evogene Reports First Quarter 2025 Financial Results

Evogene Schedules First Quarter 2025 Financial Results Release

May 8, 2025, 7:00 AM EDT - 1 year ago

Evogene Schedules First Quarter 2025 Financial Results Release

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Apr 21, 2025, 7:00 AM EDT - 1 year ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Evogene Earnings Call Transcript: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Earnings Call Transcript: Q4 2024

Evogene Annual report: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Annual report: Q4 2024

Evogene Earnings release: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Earnings release: Q4 2024

Evogene Slides: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Slides: Q4 2024

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:15 AM EST - 1 year ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Mar 6, 2025, 7:00 AM EST - 1 year ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 20, 2025, 7:00 AM EST - 1 year ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Feb 13, 2025, 8:00 AM EST - 1 year ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Evogene Slides: Company Presentation

Dec 19, 2024, 7:00 AM EST - 1 year ago

Evogene Slides: Company Presentation

Evogene Slides: Corporate Presentation

Nov 28, 2024, 7:00 AM EST - 1 year ago

Evogene Slides: Corporate Presentation

Evogene Earnings Call Transcript: Q3 2024

Nov 21, 2024, 9:00 AM EST - 1 year ago

Evogene Earnings Call Transcript: Q3 2024

Evogene Quarterly report: Q3 2024

Nov 21, 2024, 9:00 AM EST - 1 year ago

Evogene Quarterly report: Q3 2024

Evogene Reports Third Quarter 2024 Financial Results

Nov 21, 2024, 7:30 AM EST - 1 year ago

Evogene Reports Third Quarter 2024 Financial Results

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 19, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 12, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Evogene Schedules Third Quarter 2024 Financial Results Release

Nov 7, 2024, 7:00 AM EST - 1 year ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Evogene Registration statement: Registration Filing

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Evogene Registration statement: Registration Filing

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Aug 23, 2024, 8:55 AM EDT - 1 year ago

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Evogene Earnings Call Transcript: Q2 2024

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Evogene Earnings Call Transcript: Q2 2024

Evogene Earnings release: Q2 2024

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Evogene Earnings release: Q2 2024

Evogene Reports Second Quarter 2024 Financial Results

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2024 Financial Results

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Aug 12, 2024, 7:11 AM EDT - 1 year ago

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Schedules Second Quarter 2024 Financial Results Release

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2024 Financial Results Release

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

Jul 31, 2024, 7:00 AM EDT - 2 years ago

Casterra Announces the Completion of a Successful Castor Seed Growing and Harvesting Season in Brazil

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

Jul 23, 2024, 8:48 AM EDT - 2 years ago

Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split

ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants

Jul 17, 2024, 8:00 AM EDT - 2 years ago

ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants

ICL

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

Jul 2, 2024, 7:00 AM EDT - 2 years ago

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

opgntozero
opgntozero Jun. 4 at 10:40 AM
$EVGN Strange, our highly praised CEO from Haviv earns almost $500,000 a year without bonuses and never buys a single share of Evogene Evogene is valued at $6 million! This entire management at Evogene is simply insane and unprofessional https://www.linkedin.com/posts/evogene_financialresults-biotechnology-lifesciences-activity-7462822232491466752-iNMU
0 · Reply
SuperBusa
SuperBusa Jun. 3 at 3:49 PM
$EVGN
0 · Reply
daytradeforlife
daytradeforlife Jun. 3 at 11:27 AM
$EVGN wtf is happening?!?!
1 · Reply
Moneymike314
Moneymike314 Jun. 2 at 7:41 PM
$EVGN bottom is in, could cause a run back to .65+
0 · Reply
cw9c
cw9c Jun. 2 at 7:36 PM
$EVGN so how are we supposed to feel about today as shareholders of this company? I mean I don't feel like I can trust management anymore if there are clearly behind the scenes actions going on that thwart any value to shareholders.
0 · Reply
Stockyear
Stockyear Jun. 2 at 6:56 PM
$EVGN This was clearly an attack by option traders to short the stock. The company has a successful test per their press release today.
2 · Reply
opgntozero
opgntozero Jun. 2 at 6:23 PM
$EVGN The persistent underperformance of Evogene has led many investors to lose confidence in its potential for recovery or growth. There seems to be a troubling disconnect between the interests of management and those of shareholders. Many feel that rather than prioritizing the creation of shareholder value, there is a focus on personal financial gain for executives. Evogene stock will go to $ 0! 100%! over haviv youre not a ceo ...anything else https://www.linkedin.com/posts/evogene_microbiometherapeutics-oncologyinnovation-activity-7467537264357687297-K6Ug
0 · Reply
cw9c
cw9c Jun. 2 at 5:21 PM
$EVGN holy hell I screwed up today...this is soo bad...I mean the volume this morning had to have literally just be dilution
2 · Reply
ikerrr
ikerrr Jun. 2 at 4:03 PM
$EVGN I think it pops before the day s over
2 · Reply
cw9c
cw9c Jun. 2 at 3:59 PM
$EVGN like every slight move up is just a balloon being shot down
0 · Reply
cw9c
cw9c Jun. 2 at 2:54 PM
$EVGN never seen such a deflated stock…I mean is this company that bad?
0 · Reply
cw9c
cw9c Jun. 2 at 2:08 PM
$EVGN good news and now all it can do is trade at 10% down
0 · Reply
cw9c
cw9c Jun. 2 at 1:12 PM
$EVGN man I had been having a good couple of weeks and then this s***show...why even drop news at this point? They're literally at 52 week if not all time lows right now.
0 · Reply
cw9c
cw9c Jun. 2 at 1:07 PM
$EVGN well at least they are a good-at-heart company trying to cure cancer...now they're just killing their shareholders but seems like a reasonable trade off, right?
0 · Reply
quicktwitted
quicktwitted Jun. 2 at 12:57 PM
$EVGN putting thisvon list of Chinese scam companies...break room is full of chop sticks im sure
0 · Reply
ChartBill
ChartBill Jun. 2 at 12:37 PM
$EVGN hit my stop loss and then this mini bounce, nice
0 · Reply
SuperBusa
SuperBusa Jun. 2 at 12:32 PM
$EVGN
0 · Reply
kylewilliam762
kylewilliam762 Jun. 2 at 12:21 PM
$EVGN it has never been this low in its history of trading, wtf 🥴😬
0 · Reply
Olivia_Strickland
Olivia_Strickland Jun. 2 at 12:19 PM
$EVGN now red, down 16% premarket after popping yesterday. these vertical pops giving it all back, no catalyst on my feed either way. 295x its 10-day vol on a $6M cap. fade looks like it's already underway. calling it green by no one's stop, who's still in?
1 · Reply
cw9c
cw9c Jun. 2 at 12:19 PM
$EVGN 52 week low on positive news...WTF is wrong with the U.S. market these days?
0 · Reply
cw9c
cw9c Jun. 2 at 12:17 PM
$EVGN what's even scarier is this doesn't look like it has any bounce in it...any 0.01 jump is immediately deflated...I mean this could literally go under 0.50 today...
0 · Reply
cw9c
cw9c Jun. 2 at 12:07 PM
$EVGN 40k in volume to over 18 million in PM and we are down 10%...how?
0 · Reply